Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer – a multicenter study

Vol. 44 (5): 892-899, September – October, 2018

doi: 10.1590/S1677-5538.IBJU.2017.0632


ORIGINAL ARTICLE

Aline B. Mattiolli 1, Allan Santos1,2,3, Andreia Vicente 3, Marcelo Queiroz 3, Diogo Bastos 3, Daniel Herchenhorn 4, Miguel Srougi 3, Fabio A. Peixoto 5, Lisa Morikawa 4, 5, João Luiz Fernandes da Silva 3, Elba Etchebehere 1, 2, 3
1 Universidade Estadual de Campinas (UNICAMP), Campinas, Brasil; 2 Medicina Nuclear de Campinas, Campinas, SP, Brasil; 3 Hospital Sírio – Libanês, São Paulo, SP, Brasil; 4 Centro de Oncologia de D’Or, Rio de Janeiro, RJ, Brasil; 5 Grupo Américas Centro de Oncologia Integrado, Rio de Janeiro, RJ, Brasil

ABSTRACT

Purpose: The purpose of our study was to evaluate the clinical impact of 68Ga-PSMA PET / CT in the setting of biochemical recurrence of prostate cancer.

Materials and Methods: We retrospectively evaluated 125 prostate cancer patients submitted to the 68Ga-PSMA PET / CT due to biochemical recurrence. The parameters age, Gleason score, PSA levels, and the highest SUVmax were correlated to potential treatment changes. The highest SUVmax values were correlated with age and Gleason score. The median follow-up time was 24 months.

Results: 68Ga-PSMA PET / CT led to a treatment change in 66 / 104 (63.4%) patients (twenty-one patients were lost to follow-up). There was a significant change of treatment plan in patients with a higher Gleason score (P = 0.0233), higher SUVmax (p = 0.0306) and higher PSA levels (P < 0.0001; median PSA = 2.55 ng / mL).

Conclusion: 68Ga-PSMA PET / CT in prostate cancer patients with biochemical recurrence has a high impact in patient management.

Keywords: Prostatic Neoplasms; Tomography, X-Ray Computed; Positron-Emission Tomography

[Full Text]


print

Related Post